Patents by Inventor Alexandre Dubrac

Alexandre Dubrac has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Mutants PF4 polypeptides exhibiting an increased anti-angiogenic activity
    Patent number: 8940702
    Abstract: The present invention pertains to PF4 muteins which comprise a substitution at position 67, e.g. a L67H substitution, compared to the sequence of the wild-type PF4 protein. Such PF4 muteins exhibit an increased anti-angiogenie activity and a reduced affinity for proteoglycans compared to the wild-type PF4 protein.
    Type: Grant
    Filed: July 26, 2010
    Date of Patent: January 27, 2015
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Universite de Bordeaux
    Inventors: Andreas Bikfalvi, Herve Prats, Cathy Quemener, Alexandre Dubrac
  • Neutralizing antibodies and fragments thereof directed against platelet factor-4 variant 1 (PF4V1)
    Patent number: 8481033
    Abstract: The present invention relates to neutralizing antibodies and fragments thereof directed against Platelet Factor-4 variant 1 (PF4v1) and their use for treating pathologies that require induction of angiogenesis or diseases associated with pathological angiogenesis.
    Type: Grant
    Filed: October 7, 2009
    Date of Patent: July 9, 2013
    Assignee: INSERM (Institute National de la Santé et de la Recherche Médicale)
    Inventors: Andreas Bikfalvi, Alexandre Dubrac, Eric Lacazette, Herve Prats
  • MUTANTS PF4 POLYPEPTIDES EXHIBITING AN INCREASED ANTI-ANGIOGENIC ACTIVITY
    Publication number: 20120157384
    Abstract: The present invention pertains to PF4 muteins which comprise a substitution at position 67, e.g. a L67H substitution, compared to the sequence of the wild-type PF4 protein. Such PF4 muteins exhibit an increased anti-angiogenie activity and a reduced affinity for proteoglycans compared to the wild-type PF4 protein.
    Type: Application
    Filed: July 26, 2010
    Publication date: June 21, 2012
    Inventors: Andreas Bikfalvi, Herve Prats, Cathy Quemener, Alexandre Dubrac
  • CXCL4L1 AS A BIOMARKER OF PANCREATIC CANCER
    Publication number: 20110318370
    Abstract: The invention relates to the use of CXCL4L1 as a biomarker of pancreatic cancer in a patient. More particularly, the invention relates to a method for detecting a pancreatic cancer and/or pancreatic metastasis in a patient, said method comprising determining the expression level of the CXCL4L1 gene in a biological sample obtained from said patient.
    Type: Application
    Filed: November 25, 2009
    Publication date: December 29, 2011
    Inventors: Andreas Bikfalvi, Herve Prats, Alexandre Dubrac, Martin Hagedorn
  • Neutralizing Antibodies and Fragments Thereof Directed Against Platelet Factor-4 Variant 1 (PF4V1)
    Publication number: 20110250210
    Abstract: The present invention relates to neutralizing antibodies and fragments thereof directed against Platelet Factor-4 variant 1 (PF4v1) and their use for treating pathologies that require induction of angiogenesis or diseases associated with pathological angiogenesis.
    Type: Application
    Filed: October 7, 2009
    Publication date: October 13, 2011
    Inventors: Andreas Bikfalvi, Alexandre Dubrac, Eric Lacazette, Herve Prats